Age Age Range Mean

30-73 43

Nuclear Grade Grade-I Grade-II Grade-III No Data

10(50%) 7(35%) 2(10%) 1(5%)

Lymph Node Positive 0 1-3 4-9 Above 10

7(36.84%) 6 (31.5%) 4(21.05%) 2 (10.5%)

Hormonal Status ER+/PR+ ER-/PR- ER+/PR-

8(40%) 11(55%) 1(5%)

Her-2 Status Her-2 Positive Her-2 Negative

10(50%) 10(50%)

Menopausal Status Postmenopausal Premenopausal

13(65%) 7(35%)

Chemotherapy Adriyamycine, 5FU, Endoxane

20(100%)

No cases of ER−/PR+ were identified in this group
Table 2: Clinical and pathological features of 20 invasive breast patients in qRT-PCR analysis.